Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 12/20 | 0.52 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | FPR3 | P25089 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19208477 | 1.00 | CFD (0.52) | CFDP2RX7ALDH1A1FPR3FPR2 | |
| SCHEMBL19208351 | 0.84 | CFD (0.52) | CFDP2RX7ALDH1A1FPR3FPR2 | |
| SCHEMBL19208352 | 0.84 | CFD (0.52) | CFDP2RX7ALDH1A1FPR3FPR2 | |
| SCHEMBL28803220 | 0.82 | CFD (0.50) | CFDP2RX7 | |
| SCHEMBL28803219 | 0.82 | CFD (0.50) | CFDP2RX7 | |
| SCHEMBL21003683 | 0.81 | P2RX7 (0.48) | CFDP2RX7ALDH1A1NPC1RAB9A | |
| SCHEMBL19208359 | 0.81 | CFD (0.58) | CFDP2RX7ALDH1A1FPR3FPR2 | |
| SCHEMBL19208432 | 0.80 | CFD (0.50) | CFDP2RX7ALDH1A1NPC1RAB9A | |
| SCHEMBL19208429 | 0.80 | CFD (0.50) | CFDP2RX7ALDH1A1NPC1RAB9A | |
| SCHEMBL3163916 | 0.78 | P2RX7 (0.64) | CFDP2RX7ALDH1A1FPR3FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12485109-B2 | Pyrrolo 12.3-dipyrimidine compounds and analogues thereof | BIOCRYST PHARMACEUTICALS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| EP-3925956-B1 | 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS | BIOCRYST PHARM INC (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20230218578-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-07-13 | — | — | US | disclosed |
| US-20230218578-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-07-13 | — | — | US | disclosed |
| US-11559515-B2 | Indole compounds and analogues thereof | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-11559515-B2 | Indole compounds and analogues thereof | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| CN-115490751-A | Factor D inhibitors | 拜奥克里斯特制药公司 | 2022-12-20 | — | — | CN | disclosed |
| CN-109121414-B | Benzopyrazole compounds and analogs thereof | 拜奥克里斯特制药公司 | 2022-07-05 | — | — | CN | disclosed |
| EP-3411411-B3 | 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS | BIOCRYST PHARM INC (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3411411-B3 | 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS | BIOCRYST PHARM INC (US) | 2022-01-26 | — | — | EP | disclosed |
| US-10849883-B2 | Benzopyrazole compounds and analogues thereof | BIOCRYST PHARMACEUTICALS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190292155-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHARMACEUTICALS INC (BB) | 2019-09-26 | — | — | US | disclosed |
| US-20190292155-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHARMACEUTICALS INC (BB) | 2019-09-26 | — | — | US | disclosed |
| US-20190142802-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | BIOCRYST PHARMACEUTICALS, INC. (US) | 2019-05-16 | — | — | US | disclosed |
| US-20190142802-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | BIOCRYST PHARMACEUTICALS, INC. (US) | 2019-05-16 | — | — | US | disclosed |
| EP-3411411-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | Biocryst Pharmaceuticals, Inc. (US) | 2018-12-12 | — | — | EP | disclosed |
| WO-2018015818-A2 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHARMACEUTICALS, INC. (BB) | 2018-01-25 | — | — | WO | disclosed |
| WO-2018015818-A2 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHARMACEUTICALS, INC. (BB) | 2018-01-25 | — | — | WO | disclosed |
| WO-2017136395-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | BIOCRYST PHARMACEUTICALS, INC. (US) | 2017-08-10 | — | — | WO | disclosed |
| WO-2017136395-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | BIOCRYST PHARMACEUTICALS, INC. (US) | 2017-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12485109-B2 | Pyrrolo 12.3-dipyrimidine compounds and analogues thereof | C5, DPYD, C9 | CFD 40/4885P2RX7 622/4885ALDH1A1 1373/4885 |
| US-20230218578-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | C9, C5, C1QBP | CFD 13/4885P2RX7 501/4885ALDH1A1 1023/4885 |
| US-11559515-B2 | Indole compounds and analogues thereof | C5, IDO1, IDO2 | CFD 25/4885P2RX7 2231/4885ALDH1A1 1113/4885 |
| US-10849883-B2 | Benzopyrazole compounds and analogues thereof | C9, C5, C1QBP | CFD 13/4885P2RX7 501/4885ALDH1A1 1023/4885 |
| US-20190292155-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | CFD, C9, CFH | CFD 1/4885P2RX7 1792/4885ALDH1A1 3221/4885 |
| US-20190142802-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | C9, C5, C1QBP | CFD 13/4885P2RX7 501/4885ALDH1A1 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.